Completes $11 mil. venture financing, its third, and has raised $22.8 mil. to date. Leading the new round of financing was Schroder Ventures. Other new investors included SenMed Medical Ventures, Technology funding and Blue Cross/Blue Shield of Iowa. All current investors also participated. The South San Francisco- based protease/protease inhibitor R&D firm was founded by Genentech, which has an equity stake in the company
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth